Good morning, ladies and gentlemen, and welcome to the Akebia Therapeutics' INNO2VATE Top-line Data Readout Call and its First Quarter Financial Results and Business Highlights Conference Call. As a reminder, this call is being recorded. I would now like to introduce your host for today's conference, Kristen Sheppard.

Thank you, and good morning. My name is Kristen Sheppard, Senior Vice President of Investor Relations at Akebia. Thank you so much for joining us to discuss Akebia's Top-line data for INNO2VATE, our global Phase 3 program of our product candidate, vadadustat, for the treatment of anemia due to chronic kidney disease in adult dialysis-dependent patients. On today's call we will also discuss Akebia's first quarter 2020 financial results and our recent business highlights. We issued two press releases this morning; one containing INNO2VATE's top-line data, followed by one containing our financial results and other recent business highlights. Both of these exciting press releases are available on our Investor Relations Web site along with the slides for today's call. For your convenience, an audio replay of today's call, with the slides, will also be available on our Web site shortly after we conclude today's webcast. Joining our call today are John Butler, President and Chief Executive Officer; Dr. Steven Burke, Chief Medical Officer; and Jason Amello, Chief Financial Officer. Before we begin, I'd like to remind everyone that this conference call includes Forward-Looking Statements. Each forward-looking statement contained in this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information regarding these factors is described in the Risk Factors and Management's Discussion and Analysis sections of our most recent quarterly and annual reports filed with the SEC, and in the cautionary note on forward-looking statements in the slides. The forward-looking statements on this call speak only as of the original date of this call and we do not undertake any obligation to update or revise any of these statements. With that, I'd like to turn the call over to our CEO, John Butler. John?

Thank you, Kristen, and welcome to everyone. We are thrilled to be able to announce positive top-line data from INNO2VATE, the first of our two global Phase 3 programs studying vadadustat, our investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, to treat the anemia of chronic kidney disease. It is extremely rewarding to see this program yield clear, consistent, and compelling positive results. This is a very important day for Akebia, but it was not accomplished by the Akebia team alone. I want to sincerely thank our investigators and their staff for participating, but most importantly, I want to thank the nearly 4,000 patients who participated in this program. Dialysis patients are among the most at risk and hardest hit by COVID-19. During these uncertain times, we're reminded of both the critical nature of our work and the significant need to advance care for these patients. I'd also like to thank our collaboration partner, Otsuka, our partner in dialysis, Vifor Pharma, and our shareholders for supporting Akebia and our efforts thus far. The Akebia team did an extraordinary job closing the studies, collaborating and analyzing the data despite the logistical challenges of operating under the present COVID environment, brining INNO2VATE to a timely and successful conclusion. I'm extremely proud of all of our employees. We believe our collective efforts bring us one step closer to fulfilling our purpose to better the lives of each person impacted by kidney disease. Again, my sincere thanks to everyone, we wouldn’t be here today without all of you. In terms of an agenda for today's call, we're going to start with looking at how COVID-19 is impacting our business and how we are working to mitigate potential impacts. We issued our initial response to COVID on March 15, and today I'll provide some…

Thank you, John, and good morning everyone. On behalf of the R&D team at Akebia, we're very excited to share these data today. As John mentioned, anemia due to CKD is a serious condition characterized by decreased hemoglobin and is associated with cardiovascular events, hospitalization, and mortality, as well as increased risk of CKD progression. The burden of CKD has a significant impact on patient quality of life, and adds significant costs to our healthcare system. Anemia is currently treated with injectable ESAs, along with iron supplementation or red blood cell transfusions. While ESAs are effective in raising hemoglobin levels, there are well-documented safety risks associated with their use. In particular, there was evidence that patients administered higher doses of ESAs experienced an increased risk of adverse cardiovascular events, particularly stroke and also mortality. Considering the unmet medical need for safe and effective treatment, we believe INNO2VATE data are compelling and advance our plans for an NDA the potential approval of vadadustat. Based on Nobel Prize winning science, vadadustat was designed as a once-daily, orally-administered investigational HIF-PHI to mimic the body's natural physiologic response to hypoxia or low oxygen. By stabilizing HIF, vadadustat up-regulates transcription of endogenous erythropoietin in proteins involved in iron absorption, transport, and utilization. The increase in erythropoietin in delivery of iron to the bone marrow leads to increased red blood cell production in higher hemoglobin. The INNO2VATE program was well powered for efficacy and cardiovascular safety, and included to Phase 3 studies: correction, conversion, and conversion, which collectively enrolled 3,923 dialysis-dependent patients with anemia due to CKD. This is a very large, rigorous, and thoughtfully-designed program to compare vadadustat to a current standard of care, darbepoetin alfa in injectable ESA. As illustrated on slide 4, both INNO2VATE studies were global multi-center open label, but sponsor-blind non-inferiority…

Thanks, Steve. We believe we have a strong, compelling, and very straightforward dataset for vadadustat. In terms of what's next, I will remind you that INNO2VATE is the first of many potentially transformational near-term milestones. We believe we have developed an exciting path forward for vadadustat and Akebia, and although the COVID-19 environment remains uncertain, we continue to make solid progress advancing these activities. In collaboration with our partner, Mitsubishi Tanabe, we're advancing key pre-commercial activities in support of the first regulatory approval of vadadustat expected in Japan this year. Upon approval vadadustat is expected to be the first HIF-PHI that would be available to treat anemia due to CKD in both dialysis and non-dialysis dependent adult patients in a major market. As I mentioned earlier, we have significantly advanced PRO2TECT, our global Phase 3 study evaluating the safety and efficacy of vadadustat in non-dialysis dependent adult patients with anemia due to CKD. We've achieved the target number of MACE events for the study and expect top line data mid-year as planned. In addition, we reinforced our intellectual property position for vadadustat confirming for both Akebia and our collaboration partner Otsuka are positioned to execute on plans to launch vadadustat in the U.K., and potentially the rest of Europe upon approval. We can't wait to get these data in front of the FDA and other regulatory agencies as soon as possible. Upon successful completion of our Phase 3 program, and with PRO2TECT data in hand, we plan to submit the regulatory filings for marketing approval of vadadustat for both dialysis dependent and non-dialysis adult patients in the U.S. as quickly as possible. And then in other regions in collaboration with Otsuka and that's not all. We have an agreement with Vifor Pharma to potentially access to Priority Review Voucher or…

Thank you. [Operator Instructions] Our first question comes from Chris Raymond with Piper Sandler. Your line is now open.

Hi this is Ally Bratzel on for Chris. Congrats on the data. So, first, just on PRO2TECT, I know you've talked about this a bit in the prepared remarks, but can you just talk about your confidence and being able to disclose the pre-dialysis data midyear, and the ability to file an NDA later this year, And how maybe we should adjust our timing expectations if COVID is still in full swing at that point? And then, just generally on the actual pre-dialysis readout, how does INNO2VATE change your confidence in reaching the main endpoint in PRO2TECT?

Thanks, Ally. Thanks for the questions. So as I mentioned, PRO2TECT is on time for mid 2020, I mean we're obviously continuing to monitor the COVID situation, but as of today, we feel very confident that we'll be able to deliver that data in mid 2020, and then we'll move as quickly as possible to a filing, and obviously the timing will be dependant on when we get the PRO2TECT data, but it's an incredibly exciting moment for us. And to your second question around how does INNO2VATE influence, how we feel about PRO2TECT, now look, I think it's important that the design is identical, basically that we're looking at PRO2TECT with the same active control, the same data collection, et cetera. At the same time, it's a different program. So, we'll see this data very, very soon, and we can't wait to see it, and we couldn’t be more excited about the path we have going forward.

Great. And then maybe another question on the non-inferiority margin, so you indicated you'd agreed to -- prospectively agreed with FDA to MACE non-inferiority margin of 1.25, but 1.3 for EMA. Could you talk about why the agencies differ, or maybe how you and FDA came to the agreement on that 1.25 number when I think in the past for [renal drug] [Ph] they only asked for 1.3, and then maybe if you can address if there's any reason to think FDA would look for a different non-inferiority margin for PRO2TECT for the pre-dialysis program.

So, it was extensive dialogue with both regulatory agencies, and we're very comfortable with where we landed with both, and most importantly, when you look at the data, with an upper bound of 1.11 we're comfortably within the non-inferiority range for either regulatory authority. So we're very, very pleased with what we've shown you today, and again, we're hoping to show the same from PRO2TECT.

Great. And then, maybe just last question for me, could you talk about your current expectations for a potential [AdCom] [Ph] for vadadustat?

Well, that's -- an AdCom is up to the FDA. So we'll wait and see. We'll have both sets of data to put in front of them as quickly as we can, and we can't wait to put this data in front of the regulators. So if they want to have an AdCom, we'll be very ready for it.

Okay, great. Thanks so much, and congrats again.

Thanks, Ally.

Thank you. Our next question comes from Eric Joseph with JPMorgan. Your line is now open.

Hey guys, thanks for taking the questions, and congrats on the Phase 3 readout here. John, I wanted to pick up on your comments about how these studies were designed, and you deliberately chose to go against the design to compare the studies against standard of care. Can you just speak to how nephrologists view the relative risk benefit of [indiscernible] versus Epogen, or darbepoetin alfa versus -- darbepoetin alfa, and whether there's any meaningful distinction here, and that sort of might aid in our ability to make sort of crosstalk comparisons from INNO2VATE to the dialysis [clinic studies] [Ph] with roxadustat?

Eric, I didn’t understand the last part of that question. I didn’t hear you clearly.

Sure. There's going to be some motivation to try to make crosstalk comparison between vadadustat and roxadustat. You have different comparators between the two outcome studies. You're using darbepoetin and versus their Epogen, I'm just wondering if you could speak to how physicians view the relative risk benefit profile of the two competitors -- of the different ESAs?

So, what physicians are looking for, Eric, is clear, straightforward, and consistent data, and that's what we've delivered them today, and importantly, when you think about vadadustat, the fact that we have same comparator in INNO2VATE and PRO2TECT, this is all part of how we design the program for clinical, regulatory, and commercial success. We've got the first step with clinical success with INNO2VATE, and believe the clarity of this data and how straightforward it is will lead to regulatory and commercial success for us as well.

Got it. And just coming back to potential -- and just wondering to -- going back to this potential impact from the COVID pandemic, is there any -- well, is there any impacts in the INNO2VATE readout here where patients were unable to come in for their, I guess, secondary efficacy follow-up assessments, and I guess whether you anticipate any impact on whether -- yes, sorry, whether there's any impact from COVID in the full collection of the data in INNO2VATE and how you might anticipate any impact it affects from the pandemic as well?

Sure, Eric. I'll ask Steve to address that.

Yes, hi, Eric. No, there wasn’t any issue because we announced completion of this -- we met our MACE at the end of last year, and so we told the sites to bring their patients back as soon as possible, and so, they made their end-of-treatment visits and the end-of-study visits were allowed to be done by phone, in any case by the protocol. So it had really no impact on our ability to collect the data. And with PRO2TECT, obviously there's still some time to come, but given the experience we had with INNO2VATE we feel like we're confident in the mid-2020 timeline, but we'll update that if we need to on COVID, but obviously we've been looking really closely at it, and feel very confident in the timing.

Got it. Thanks for taking the questions.

Thanks, Eric.

Thank you. Our next question comes from Difei Yang with Mizuho Securities. Your line is now open.

Hi, good morning, first of all, congratulations on the Phase 3 readout, and just a couple questions. How should we think about non-inferiority margins for the NDD population, is it a reasonable assumption what you have reached agreement with the regulatory agency in DD can be carried over to NDD? Then the second question is that would you give us an update on the -- whether the final agreement with Vifor was signed and what's the status on that, and then finally, maybe if Jason could comment on cash runway?

Great. So thanks, Difei. So the 1.25 non-inferiority margins that we had for INNO2VATE is the same non-inferiority margin we're using for PRO2TECT. So, that's very clear, and similarly with EMA at 1.3. That was the first question. The second question was?

On Vifor…

Vifor, yes, thank you. So that's still -- we're still working through that. There was no urgency to get that finalized. Feel very confident in being able to make that happen and obviously with this data in hand we're all very excited to put that in place, and then on the cash runway side, Jason, you want to take that?

Sure. Hi, it's Jason. So our cash runway remains on guidance as we previously communicated with our year-end and with this release as well, staying well into Q 2021 we feel very confident with our cash position with that kind of a runway. And so that hasn’t changed. And we've also, to get to that level of runway, previously we've identified cost savings and efficiencies to enable us to do that, which also positions us well given the current pandemic situation. So we feel very confident with our cash position.

Thank you, Jason. And just one quick follow-up with regards to the FDA filing timeframe, so is it a reasonable assumption typically for, if PRO2TECT is positive, the typical lag time and the readout is a couple of quarters?

I'm sorry, about…

Timing.

Oh, so, Difei, we are not guiding on exact timing for filing. When we have PRO2TECT in hands, then I think we will be better able to do that, and the message I want you to hear is that when we get PRO2TECT, we will work or actually not when we get PRO2TECT, we are working already to be -- to invest quickly as possible through NDA filing, but with PRO2TECT in hand that will be the gating item. So, we will be moving. Like I said before, we are so excited about this. We want to get this front of regulators as quickly as possible, and I mean kind of come back to your last question. It’s so sudden to be in a place where we have a strong cash position, one set of Phase 3 data in hand, and then multiple other exciting milestones that are right in front of us. We have Japan approval and PRO2TECT data. So, the company is in incredible strong position right now.

Thank you so much for taking my questions, and congrats again.

Thank you, Difei.

Thanks so much, Difei.

Thank you. Our next question comes from Bert Hazlett with BTIG. Your line is now open.

Thank you, and let me offer my congratulations as well, quite an effort and terrific result. In terms of the MACE endpoint that readout, were there any components of the MACE all-cause mortality, MI, or stroke that were stronger than others? I know you are releasing top line data today, but if you could guide a little bit that might be helpful?

Yes, Bert, you said we are releasing top line data today. But -- I think the headline for you is consistent. This data was incredibly consistent across efficacy, safety, and MACE as the most important safety and that includes all the components as well.

Okay, thank you. And then, let me try to come at the same question with regard to treatment serious TEAEs. It looked like there was a little bit lower serious treatment emergent adverse events on the vadadustat -- with utilizing vadadustat. Can you make any general comments about what you are seeing there on the safety side?

Again, we are incredibly pleased with the safety that I will ask Steve to make some comments.

Yes, I think the overall safety profile was very positive, and including there was no cases of high prevalent incidents. As you remember we had a single case a long time ago. And when we looked at hepatotoxicity, no difference between the treatment groups, so, very, very pleased with all of the safety data that I have seen today.

Okay, thank you. And then just one more question regarding Vifor Pharma and the use of the priority review voucher, could you just go through the decision tree that you are going to use to whether or not you effect that transition? Just a little bit more color would be helpful.

Yes, sure, Bert. So, obviously the first step will be to come to agreement on the final economics around the PRV, and that’s -- like I said that’s an active process and I don’t have any concerns that we will get that done. The data that we have generated here with INNO2VATE would support -- absolutely support using a PRV. Like I keep saying, I can’t wait to get this data in front of regulators. It’s that clean and clear and consistent. So, but obviously we will have that conversation with Vifor, and again I think they will agree. I think they will be as excited about this data as we are.

Terrific. Let me slide in more if I could, the WuXi supply deal, could you just comment on why you felt the need to have a third commercial supply agreement in place for vadadustat?

So, we actually have two API suppliers, and that is obviously just minimizing any kind of supply risk. So, on the API side, we have [indiscernible] and WuXi, and then we also have the third supplier is for drug product, API.

Okay, thank you. Congratulations again.

Thanks, Bert.

Thank you. Our next question comes from Chad Messer with Needham. Your line is now open.

Great, thanks. Good morning, and let me add my congratulations on the data. We have obviously been working hard to get to this point. Is there any comment you can make on excursion data and how that looks? I know in your opening remarks, you've commented on guests and how one of the great promises of this class is giving very physiological and consistent hemoglobin response.

Yes. Again, Chad, what you should hear from me is the level of excitement. We're not going to go into specifics of that data. It will be presented with the data, hopefully at ASN. That's our expectation, but again, I mean we've talked before about the Spherix data that was done, it's independent research, and we talked about it from Q1 at what are physicians looking for in order to adopt a new treatment for anemia? And that is one of the key areas. First and foremost, it is a physiological level, a gradual increase in hemoglobin, avoiding excursions, and a convenient oral dose. We have proven across our development program that we can do that INNO2VATE data absolutely supports that as well. So, we feel like we're positioned incredibly well from a commercial perspective, as well as from a regulatory perspective.

Okay, thanks. That's helpful, and of course, we look forward to seeing the rest of the data when it's available. And maybe just also update on the regulatory process in Japan, I know your partner filed last July. Is the expectation still for potential approval this summer, and any updates on regulatory interactions there, and maybe can you comment on how long it takes to sort of launch and get reimbursement in general?

So, thanks for the question. We are working closely with Mitsubishi on pre-commercialization activities. Everything seems to be on track there, and as we've talked about before, if PMDA takes the normal 12-month cycle, it will be a July approval. And as I said, we're working on pre-commercialization, it will be -- we will move or our partner, Mitsubishi, will move as quickly as possible to launch the product. We certainly expect it to be launched this year.

Okay, great. Thanks, and congrats again.

Thanks, Chad.

Thank you. Our next question comes from Ed Arce with H.C. Wainwright. Your line is now open.

Hi, everyone. Thanks for taking my questions, and congrats on this very positive data set for your Phase 3, and look forward to the next one soon. A few questions for me, mostly for Dr. Burke; first is, were there any deaths in either the study or either study? Second is, if you could discuss a bit more on how the titration of the drug either up or down compares to the level of titratation? In other words, how active that was relative to Aranesp in the study? And then, thirdly, with the treatment emergent events, I see here that the numbers were very consistent and similar, but if you look at, in particular, hypertension and diarrhea, the two studies looked like numerically, one was higher, and one was lower, perhaps you could discuss anything you might have seen there with those two? And then, I have a follow-up. Thank you.

Sure. We had a technical difficulty here. So, I heard the first question and the third, but not the second. So, let me hear two the first two that I remember. Starting with third question, so the conversion study was much larger, it's almost 10 times this largest Correction/Conversion study. So, I would put more stock in the AD table for that study, and the smaller the study, the less reliable are the results. So, and the first question was death, yes, well, as you know the primary safety measure was MACE, which includes death all cause death in non-fatal stroke and non-fatal MI, and the majority of the events in the MACE analysis were deaths, and when you look across the entire study, there were fewer deaths in the vadadustat-treated patients and they were in the darbepoetin-treated patients. So, again, as John alluded to earlier, very consistent safety results around the MACE endpoint, and this is the middle question, I'm sorry.

Okay. Fair enough. So, the second question was around the titration schedule. You started with 300, and then went either up or more likely -- or down or more likely up after week-four, I was just wondering how active throughout the study that titration was on drugs relative to the competitor Aranesp, and its own schedule?

Yes, the drugs could be titrated starting at week-four, and they weren't titrated up or down, as you indicated. I am still analyzing the last data. So, I don't know how frequently the doses were adjusted in a very granular sense, but we have that data, and that'll be presented, and the key was you were titrating to get into the target range for both, and we were successfully able to do that unsurprisingly with both drugs, and it was very, very clear.

Great. And then just one last question from me, on the slide deck that you presented this morning, slide nine here on the Kaplan-Meier curve, it does look like there is a sudden increase on the darbepoetin events at about 168 weeks, any comment you wish to make there?

Well, that's just the nature of the Kaplan-Meier curves. If you look at the bottom of the slide, the number of people at risk for having a MACE event decreases over time, and when you get to the very end of the study, one event can have a significant impact on the appearance of the Kaplan-Meier curve, but I would discourage you from looking at the end of Kaplan-Meier curves and look towards more the beginning and the middle. Once you see big jumps, or long flat stretches, it means it's very few patients at risk.

Understood, thanks again.

Thanks, Ed.

Thank you. Our next question comes from David Lebowitz with Morgan Stanley. Your line is now open.

Hello. Well, thank you for taking my question. When you look at this data as of thus far, and you see potentially bringing this to market in the dialysis population, how do you see yourself differentiating this versus Epo versus darbepoetin, yes, your drug is an oral, but they are already going in for dialysis anyway, so there you're used to getting infusions and whatnot, what's the message with this data for dialysis?

Yes, we think this data absolutely supports our commercial opportunity in dialysis, David. Again, I go back to the answer I gave earlier, when you look at what physicians are looking for, you know, physicians, they look at that difference in Epo levels in excursions, and in a gradual increase in hemoglobin, those are all related to safety for them, and then of course, the convenient oral dose matters a lot in the non-dialysis patient and home dialysis patients, which of course we're moving to. That will be very important in dialysis as well. So, vadadustat positions extraordinarily well in both dialysis and non-dialysis versus darbepoetin alfa or any other ESA.

Thank you for taking my question.

Thank you.

Thanks, David.

Thank you. Our next question comes from Kennen MacKay with RBC Capital Markets. Your line is open.

Hi, thanks for taking the question, and congrats to the whole team, and big congrats to you John for getting the vadadustat from the start all the way to the finish line here. This is really impressive data.

Thanks, Kennen.

So, do you start along with those from roxadustat, I think really do validate the class, especially versus Aranesp in dialysis-dependent CKD actually, really yearly similar data with the exact same MACE hazard ratio. So, maybe with that in mind, I really love your perspective and the team's perspective on how this changes your thinking in pre-dialysis CKD around the PRO2TECT trial, and sort of specifically regarding how the control arm that you're using here, active Aranesp control could influence results coming out of that control arm and out of that trial, versus what we've seen from vadadustat that have utilized the placebo? And then separately, two quick housekeeping questions, one financial, one clinical; financial first, now that the dialysis data is mature, and there's going to be a much higher focus here, can you help us with sort of a ballpark for how we should model the royalty and revenue split in dialysis-dependent CKD with Vifor and Fresenius sales agreement? And then on the clinical side, you had mentioned no cases of Hy's law, which is a big relief, can you maybe just elaborate, were there any other liver signals, motor function test elevations that were seen to just help put that to bed? Thanks so much, and congrats again.

Thanks so much, Kennen. So, we're back to [technical difficulty] -- lot of different direction, no, it's great. So, again, your question about non-dialysis and PRO2TECT, I mean, look, from our perspective, and you've heard me say this for four years now, this is all about the design. We designed our program in collaboration, or certainly consultation with the FDA and EMA, and having the active control, remember, this was about regulatory success, clinical success, commercial success, and having an active control in non-dialysis is what the regulators asked for, and we're going to deliver that to them, and we want a design that was as consistent as possible across the entire program, INNO2VATE and PRO2TECT, and that's how we designed it. Now again, with INNO2VATE data in hand, as I said earlier, it's the same analysis, same design, same structure, et cetera. For PRO2TECT, now, it's a different patient population, separate study, we all have to see the data, but I think that that similar design is an important aspect of thinking about PRO2TECT. On the Vifor agreement, we haven't disclosed what the profit share with Vifor is. We've said that it is that we keep the vast majority of the profits, and of course, we split those with Otsuka. So, Vifor takes their piece and then the balance is split between Otsuka and Akebia. And then the third -- oh, Steve, do you want to talk about the LFTs?

Yes, the LFTs, you’re right, there were no cases of Hy's law in the study, and we had hepatic toxicity as an adverse event of special interest. There was no difference between the treatment groups. So, we also analyzed, look at proportion of patients who had [indiscernible] et cetera above the certain threshold, and there was no increase in that with vadadustat. So, it looked very good from hepatic safety perspective. This is one more area we are very pleased with the data, go ahead, Kennen.

No, congrats again on that clean safety profile, maybe just going back to that first question in mind, in your mind thinking about the pre-dialysis settings, CKD, would you expect an Aranesp arm to compare maybe better or worse on MACE versus placebo? Again, just thinking about the very similar data in dialysis-dependent with the active control, and thinking about maybe what that hazard ratio could look like in pre-dialysis, especially on MACE, it seems like if you [indiscernible] under one with that hazard ratio could give you a real commercial advantage in that setting competing others as -- some of the other players out there? Thanks and congrats again.

Yes, thanks, Kennen. Yes, we’re obviously just a few months from seeing that data. So, we're excited to see it. We do think that the similarity of design between INNO2VATE and PRO2TECT matters a lot, and we just can't wait to share the data. When we get it, I mean, just like -- we honestly couldn't be more happy with the data that we're sharing with you today. I wish ASM was next week, so that we could share the full data package, and I'm sure I feel similarly around PRO2TECT, but we all have to wait to see that data. The next question, please? That's it.

Thank you. This concludes our question-and-answer session. I would now like to turn the call back over to John Butler for closing remarks.

Thanks, Joanna, and thanks to all of you for joining us today. I started with -- you know, dialysis patients are among the most at risk during this pandemic, and we're doing all we can as a company to support them. That is clearly our mission. It really feels wonderful today to announce data that is a true innovation that we believe has the opportunity to significantly help these patients. Again, I want to thank the investigators and their staff. I want to thank the patients who participated in the trial, and I want to thank the Akebia team for all they did to deliver this outstanding result to us today. Thank you so much for joining us. We look forward to updating you in the future.

Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.